Home > News Center
 
Contact Us
Shanghai BravoBio Co., Ltd.
Add:Suite 14E, Building #5, Haifu Garden, 1365 Dongfang Road, Lujiazui Financial and Trade Zone, Shanghai 200127, China
Tel: +86 21 2025 5516
Fax: +86 21 2025 5517
Email: bd@bravobio.com
News Center
 
Sanofi collaborates with SK to develop pneumococcal vaccine
Mar. 20, 2014
 
Sanofi has inked a deal with South Korea's SK Chemicals to develop, produce and market the pneumococcal conjugate vaccine. SK Chemicals gets $23 million up front from Sinofi, after which both companies will invest in the project. SK Chemicals will manufacture the vaccine at its plant and hold exclusive rights in Korea. The profits generated outside Korea will be shared by both companies.
 
ViroCyt, LLC, introduced the New Rapid Virus Counter at the World Vaccine Congress in Washington
Mar. 25, 2014
 
ViroCyt, LLC, the leader in rapid virus quantification announced the new Virus Counter 3100, which was developed specifically for manufacturing environments and includes 21 CFR part 11-capable software, a 96-well compatible autosampler. The Virus Counter, first introduced in 2011, provides results in minutes instead of days or weeks which is vital when monitoring complex and expensive viral production processes.
 
Pfizer's meningococcal B vaccine candidate gets a fast-tracked FDA review
Apr. 02, 2014
 
Pfizer's meningococcal B vaccine candidate gets a fast-tracked FDA review as a breakthrough therapy, which will allow it to file for approval based on Phase II data by Q2 this year. Pfizer's candidate is primarily focused in adolescents and adults from 10 to 25, while Norvartis Bexsero is largely for infants and young children.
 
GSK's cancer vaccine failed in phase III
Apr. 02, 2014
 
GSK's cancer vaccine MAGE-A3, a novel immunotherapeutic vaccine that GSK co-developed with Agenus, failed in a Phase III lung cancer trial. The vaccine candidate also missed a shot in the Phase III trial for melanoma, failing to boost the immune system.
 
Novartis backs up BVCF to invest in drug development in Asia
Apr. 14, 2014
 
BVCF, a Shanghai-based life sciences investor, has closed its third fund with $188 million from Novartis etc, as drug development activities in China continues to heat up. Besides setting up big new R&D center in China and other Asian countries, big pharmas also look for other ways to invest in small but fast-growing area in biotech. And the trend is the setting up of new joint ventures and increasing in-licensed development projects.
 
Novartis gets government support to build new vaccine plant
Apr. 16, 2014
 
US government has backed up 3 vaccine manufacturing sites that can draft into service in the event of a pandemic, respectively one in Texas by GSK and Texas A&M University, one in Maryland by Emergent BioSolutions and the one in Holly Springs, NC by Novartis. With about $500 million support from the U.S. government, Novartis's plant will be fully operational by 2017, and will be the first of the 3 sites to be online.
 
Novartis sold its vaccine unit to GSK for $7.1B
Apr. 22, 2014
 
Novartis just inked a $7.1 billion deal with GSK, with a $5.25 billion upfront payment and up to $1.8 billion in milestones, selling its vaccines unit (excluding its flu business) to GSK. The center of the deal is Novartis's meningitis B vaccine Bexsero, which got EU approval and orphan drug designation in the U.S.
 
Sinovac got a ¥60 million government grant to produce HFMD vaccines
Apr. 28, 2014
 
Sinovac has got a ¥60 million government grant called the Dedicated Funds for Strategic New Emerging Industry Development to produce and commercialize EV71 candidate. Sinovac will use the money to build a facility with an annual capacity of 20 million doses and to bring the vaccines to the market.
 
Takeda gets a $70M fund from Japanese government to increase H5N1 vaccine capacity
May 4, 2014
 
Takeda's cell-cultured influenza vaccine for H5N1 got Japanese approval as well as a $70.2 million government grant to increase the production capacity in its state of art facility in Hakari Plant for an additional 8 million people. In 2009, the company received another government funding to build the facility. After expansion, Takeda will be able to supply the government with vaccines to protect 33 million people in the event of a pandemic.
Previous 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17 18 19 20 21 22 23 24 25 26 27 Next